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Planning for Transcatheter Caval Valve ImplantationPartho P. Sengupta, MD, Jagat Narula, MD, PHDP resence of severe tricuspid regurgitation (TR)is associated with increasing mortality andmorbidity in patients with heart failure (1). Se-
vere TR leads to reversal of blood ﬂow into the infe-
rior vena cava (IVC), resulting in wasted myocardial
work and worsening of right heart function, conges-
tive hepatopathy, and ascites. In a previous Editor’s
Page, we highlighted the peculiarities of blood ﬂow
in the right ventricle (RV) and the complexities
of right and left ventricular structure–function inter-
actions that were difﬁcult to overcome in a failing
RV (2). As an alternate approach, investigators have
suggested the use of inferior vena caval valve implan-
tation (CAVI) as a solution for reducing the delete-
rious ﬂow reversals in the portal and mesenteric
circulation developing from the presence of severe
TR and a failing RV (3–8). In this issue of iJACC,
O’Neill et al. (9) illustrate a precise approach using
3-dimensional printing of computed tomography
images for modeling optimal device ﬁtting for suc-
cessful CAVI (9). In this Editor’s Page, we have
extended these novel insights by revisiting the
physiology of venous circulation, the factors that
contribute to venous return, the hemodynamic ef-
fects of valvulation of IVC, and the potential beneﬁts
and pitfalls for heart failure patients with severe TR.
NORMAL PHYSIOLOGY OF IVC FLOW
The blood ﬂow in the aorta is pulsatile due to inter-
mittent ejection of blood from the left ventricle, with
transient reversal seen in diastole due to aortic valve
closure. By the time the blood reaches the capillaryFrom the Icahn School of Medicine at Mount Sinai, New York, New York.network and the venous system the bloodstream is
unidirectional, with minimal reversal seen in the
IVC at end-systole and end-diastole. Although the
competence of venous valves are pivotal for 1-way
circulation of the blood, these are only adapted for
preventing gravitational venous pooling and do not
require reversal of ﬂow for valve closure (10). The
ballooning of the sinus aids local pressure that is built
up to effect venous valve closure and prevent ﬂow
reversal. Valves are, however, not present in the
central venous system. The milking and suctioning
effects of abdominal and thoracic pressure variations
during the respiratory cycle result in a unidirectional
continuous ﬂow in the IVC and prevent blood pooling
in the central venous system.
The forces that help establish continuous ﬂow in
the veins are, however, multifactorial and include
cardiac chamber function, respiratory cycle, venous
anatomy, resistance, subject position, and activity
level. There are also peculiarities of vascular anat-
omy; whereas the abdominal aorta tapers in size
inferiorly, the IVC tapers in size superiorly toward the
heart (11), which creates a siphon-like effect in
modulating the forward velocity of ﬂowing venous
blood.
The existence of multiple mechanisms for effecting
continuous ﬂow in the veins, however, does not
protect from abnormal blood pooling from other
possible scenarios, such as the large reverse ﬂow seen
in patients with tricuspid regurgitation. A minute
reversal of ﬂow in IVC may be encountered at end-
systole and end-diastole. However, in patients with
severe TR, the reversal of ﬂow is seen not only in the
IVC, but also in the portal circulation, where the
continuous ﬂow is interrupted and reversed in sys-
tole. The presence of systolic reversal and added
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233volume in IVC and mesenteric venous circulation
leads to visceral congestion and increased hydrostatic
pressure, which causes hepatic, renal, and intestinal
congestion as well as ascites.
HEMODYNAMIC ROLE OF
ARTIFICIAL VALVES IN IVC
The approach to implant 2 valves in the superior and
inferior vena cava (IVC) for palliating the effects of
right heart failure in patients with severe TR was ﬁrst
proposed by Davidson et al. (3). However, the major
challenges to valve implantation in IVC include the
complex anatomy and large diameter of the IVC. It
has been suggested that, for overcoming congestion
in the IVC, valves are useful in patients within
the failing Fontan circulation (12,13) and, more
recently, within the IVC in patients with severe
tricuspid regurgitation and right heart failure (3–8).
Although in both strategies, valvulation has been
targeted for reducing the mesenteric congestion,
there are unique hemodynamic differences. The
Fontan physiology is distinct; the cardiac output in
this setting is almost exclusively pre-load dependent
and varies with gravity and respiration. During
expiration, part of the IVC blood ﬂows back into the
abdominal compartment. Valvulation of the Fontan
pathway was therefore suggested to reduce respira-
tory variations, decrease the backward congestion,
and increase pre-load and cardiac output. However,
actual chronic studies in humans have been disap-
pointing (13). Over a period of time, the valve leaﬂets
appear to become nonfunctional and completely
embedded in the vascular wall, leaving a canalized,
nonvalved conduit. It has been hypothesized that,
in the absence of a beat-to-beat cyclical closure
(in the absence of a functioning RV), the valve be-
comes nonfunctional over a period of time. Similar
ﬁndings have been reported in the clinical setting
when the Melody valve (Medtronic, Minneapolis,
Minnesota) was inserted in the tricuspid position
in patients with unfavorable RV function. Interest-
ingly, respiratory rates of over 30 breaths/min can
keep the valve-in-valves in the Fontan circuit
operational (13).
Preliminary data suggests that, contrary to the
Fontan circuit, valvulation of the short segment of
IVC between the right atrial–IVC junction could lead
to sustainable beneﬁts in patients with severe TR (4).
The use of CAVI in all previous reports has demon-
strated hemodynamic improvement via a decreased
venous regurgitation as well as diminished symptoms
of right heart failure (3–8). This was also seen in other
reports, such as a patient presented in this issue ofiJACC by O’Neill et al. (9), in whom the right heart
failure and right-sided recurrent pleural effusion was
seen to subside over a period of time. Moreover,
a recent experimental chronic animal model of severe
TR conﬁrmed the functional value of heterotopically-
implanted valves showing hemodynamic improve-
ment for up to 6 months after implantation. A
post-mortem evaluation was recently performed
3 months after the implantation in a patient who
received the ﬁrst-in-man CAVI but died due to intra-
cranial hemorrhage (14). The valve was well anchored
within the upper part of IVC while leaving the hepatic
veins unobstructed. The stent struts were well
covered by ﬁbrous tissue, and the leaﬂets were mo-
bile with sufﬁcient coaptation and without evidence
of degeneration. This initial promising use of CAVI in
patients with severe TR, however, required prospec-
tive evaluation.
There may be several technical and clinical
challenges associated with CAVI. First, CAVI only
addresses the regurgitation of TR into the IVC and
not into the superior vena cava. It has been sug-
gested that this may work as a safety valve to
prevent unnecessary increase of hemodynamic
afterload over a failing RV. However, at the same
time, the potential of collateral ﬂow through the
azygous veins (similar to superior vena cava
obstruction syndrome) may potentially limit the
clinical beneﬁts. Furthermore, the effects of chronic
congestion in the neck and central nervous system
veins remain unknown. Second, the CAVI leaﬂets
may become nonfunctional in the event there is not
signiﬁcant cyclical hemodynamic load, as seen in
the Fontan circuit. Third, CAVI may not alter the
performance of a failing RV because the increase in
afterload by exclusion of backward regurgitation
may lead to further decompensation of RV func-
tion. The exact threshold for RV function where
this strategy would lead to improvement of cardiac
function remains speculative. Finally, the use of
3-dimensional printing to understand the complex
geometry of the IVC and to test the valve size for
the given anatomy of the IVC highlights the bur-
geoning interest in direct modeling and testing
for device selection. The exact incremental value
and cost-effectiveness of 3-dimensional printing for
such scenarios, however, need to be prospectively
evaluated.
To summarize, CAVI appears to be an intriguing
strategy for patients with severe TR given the chal-
lenges associated with percutaneous treatment of the
tricuspid valve. There are newer percutaneous tech-
niques, such as bicuspidization of the tricuspid valve,
implanting an Impella (Abiomed, Danvers,
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234Massachusetts) on the right side, or catheter-
deployed percutaneous right-sided ventricular assist
devices, and the relative merits, pitfalls, and appli-
cations of these techniques will be deﬁned over the
next few years. Although technological innovations
promise new solutions, techniques in 3-dimensional
printing and advanced pre-procedural computational
modeling will be pivotal for designing personalizedapproaches for operative planning and reducing
operating time, the number of repeat interventions,
and the overall cost of the procedures.
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